Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives

Lurbinectedin is an antitumor agent belonging to the natural marine-based tetrahydroisoquinoline family which has shown very promising clinical activity with a favorable safety profile in many types of cancer. Preclinical evidence showed that lurbinectedin inhibits active transcription and binds to...

Full description

Bibliographic Details
Main Authors: Lucia Musacchio, Carlo Maria Cicala, Vanda Salutari, Floriana Camarda, Maria Vittoria Carbone, Viola Ghizzoni, Elena Giudice, Camilla Nero, Maria Teresa Perri, Caterina Ricci, Francesca Tronconi, Giovanni Scambia, Domenica Lorusso
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Oncology
Subjects:
ovarian cancer
lurbinectedin
platinum-resistant ovarian cancer
marine-derived drugs
DNA minor groove
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.831612/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.831612/full

Similar Items